Update on the use of L-asparaginase in infants and adolescent patients with acute lymphoblastic leukemia

Clinical Medicine Insights: Oncology

Volumn 8, Issue , 2014, Pages 95-100

  Andrade, Augusto F ^a   Borges, Kleiton S ^a   Silveira, Vanessa S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute lymphoblastic leukemia; Asparaginase; Molecular resistance mechanisms; Therapy updates

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; DEXAMETHASONE; ERWINIA ASPARAGINASE; ESCHERICHIA COLI ASPARAGINASE; GRASPA; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INFANT; LEUKEMIA CELL; LEUKEMIA REMISSION; LIVER DYSFUNCTION; NEUROLOGIC DISEASE; PANCREATITIS; PROGNOSIS; THROMBOSIS;

EID: 84907313793     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S10242     Document Type: Article

References (72)

1. Pinkel D. Curing children of leukaemia. Cancer. 1987;60:683.
2. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-6.
3. Pui CH, Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
4. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-8.
5. Pieters R, Carroll W.L. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 2008;55:1-20.
6. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99:2734-9.
7. Avramis VI, Tiwari P.N. Asparaginase native ASNase or pegylated ASNase in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1:241-54.
8. Ho DH, Whitecar JP Jr, Luce JK, et al. l-Asparagine requirement and the effect of l-asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970;30:466-72.
9. Pieters R, Hunger SP, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238-49.
10. Hill JM, Roberts J, Loeb E, et al. l-Asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA. 1967;202:882-8.
11. Dhanam JG, Kannan S. l-Asparaginase-types, perspectives and applications. Adv Bio Tech. 2013;13:01-5.
12. Savitri NA, Azmi W. Microbial l-asparaginase: a potent antitumour enzyme. Ind J Biotechnol. 2003;2:184-94.
13. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;86:651-8.
14. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665-79.
15. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-42.
16. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999;21:6-12.
17. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan G.R. Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukaemia: a Pediatric Oncology Group Study. Blood. 2000;96:1709-15.
18. Muller HJ, Boos J. Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;282:97-113.
19. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208-21.
20. Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000;34:200-5.
21. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman L.B. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009;53:162-7.
22. Barry E, De Angelo DJ, Neuberg D, et al. Favourable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber cancer institute acute lymphoblastic leukemia consortium protocols. J Clin Oncol. 2007;25:813-9.
23. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of l-asparaginase in children with advanced leukemia. Cancer. 1972;30:339-47.
24. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896-904.
25. Cheung NK, Chau IY, Coccia P.F. Antibody response to Escherichia coli l-asparaginase: prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol. 1986;8:99-104.
26. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527-33.
27. Asselin B.L. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-9.
28. Wenner KA, Vieira Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m2. PEG-asparaginase iv in children with acute lymphoblastic leukemia. Klin Padiatr. 2005;217:321-6.
29. Willer A, Gerss J, König T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E. coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118:5774-82.
30. Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014:2014;123:2026-33.
31. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26:217-26.
32. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Młynarski W. The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations. Clin Exp Med. 2009;9:113-6.
33. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated l-asparaginase therapy for children with relapsed acute lymphoblastic leukaemia. Clin Cancer Res. 2004;10:5335-41.
34. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119:1658-64.
35. Vrooman LM, Stevenson KE, Supko JG, et al. Post induction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202-10.
36. Loureiro CB, Borges KS, Andrade AF, et al. Purification and biochemical characterization of native and pegylated form of l-asparaginase from Aspergillus terreus and evaluation of its antiproliferative activity. Adv Microbiol. 2012;2012:138-45.
37. Mahajan RV, Kumar V, Rajendran V, Saran S, Ghosh PC, Saxena R.K. Purification and characterization of a novel and robust l-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties. PLoS One. 2014;9(6):e99037.
38. Oza VP, Trivedi SD, Parmar PP, Subramanian R.B. Withania somnifera (Ashwagandha): a novel source of l-asparaginase. J Integr Plant Biol. 2009;51:201-6.
39. Oza VP, Parmar PP, Patel DH, Subramanian R.B. Cloning, expression and characterization of l-asparaginase from Withania somnifera L. for large scale production. 3 Biotech. 2011;1:21-6.
40. Domenech C, Thomas X, Chabaud S, et al. l-Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153:58-65.
41. Aslanian AM, Kilberg M.S. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J. 2001;358:59-67.
42. Story MD, Voehringer DW, Stephens LC, Meyn R.E. l-Asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol. 1993;32:129-33.
43. Ueno T, Ohtawa K, Mitsui K, et al. Cell cycle arrest and apoptosis of leukemia cells induced by l-asparaginase. Leukemia. 1997;11:1858-61.
44. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89:2959-65.
45. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-42.
46. Andrulis IL, Argonza R, Cairney A.E. Molecular and genetic characterization of human cell lines resistant to l-asparaginase and albizziin. Somat Cell Mol Genet. 1990;16:59-65.
47. Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg M.S. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272:C1691-9.
48. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to l-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101:2743-7.
49. Stams, Wendy a G. et al. "Asparagine Synthetase Expression Is Linked with L-Asparaginase Resistance in TEL-AML1-Negative but Not TEL-AML1-Positive Pediatric Acute Lymphoblastic Leukemia." Blood. 2005;105(11):4223-25. Retrieved April 14, 2014.
50. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107:4244-9.
51. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer L.M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res. 2005;65:291-9.
52. Pastorczak A, Fendler W, Zalewska-Szewczyk B, et al. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment. Leuk Res. 2014;38:180-3.
53. Rousseau J, Gagné V, Labuda M, et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011;118:5883-90.
54. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117:1049-57.
55. Laranjeira AB, de Vasconcellos JF, Sodek L, et al. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase. Leukemia. 2012;26:1001-11.
56. Dimitriou H, Choulaki C, Perdikogianni C, Stiakaki E, Kalmanti M. Expression levels of ASNS in mesenchymal stromal cells in childhood acute lymphoblastic leukemia. Int J Hematol. 2014;99:305-10.
57. Ehsanipour EA, Sheng X, Behan JW, et al. Adipocytes cause leukemia cell resistance to l-asparaginase via release of glutamine. Cancer Res. 2013;73:2998-3006.
58. Schotte D, De Menezes RX, Akbari Moqadam F, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011;96:703-11.
59. Popovic R, Riesbeck LE, Velu CS, et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009;113:3314-22.
60. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998;12:1344-8.
61. Schotte D, Lange-Turenhout EA, Stumpel DJ, et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 2010;95:1675-82.
62. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986-94.
63. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199-205.
64. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli l-asparaginase in man. Cancer. 1970;25:253-78.
65. Pratt CB, Simone JV, Zee P, et al. Comparison of daily versus weekly l-asparaginase for the treatment of childhood acute leukemia. J Pediatr. 1970;77:474-83.
66. Raetz EA, Salzer W.L. Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554-63.
67. Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970;30:2297-305.
68. Fu CH, Sakamoto K.M. PEG-asparaginase. Expert Opin Pharmacother. 2007;8:1977-84.
69. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525-32.
70. Godfrin Y, Bertrand Y. l-Asparaginase introduced into erythrocytes for the treatment of leukaemia (ALL). Bio Med E.S. 2006;1:10-3.
71. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Cancer Group study (CCG-1941). Pediatr Blood Cancer. 2006;47:141-6.
72. Albertsen BK, Schrøder H, Jakobsen P, Müller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001;52:433-7.